Current Gleason score-Between 8 to 10 Posts on Medivizor
Navigation Menu

Current Gleason score-Between 8 to 10 Posts on Medivizor

Evaluating the effects of abiraterone acetate in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Evaluating the effects of abiraterone acetate in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Posted by on Jan 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the effects of abiraterone acetate (AA; Zytiga) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that AA and ADT combination improves the outcomes in these patients. Some background Patients with mHSPC have...

Read More

Looking for patients with high risk prostate cancer to trial a radiation treatment

Looking for patients with high risk prostate cancer to trial a radiation treatment

Posted by on Aug 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to investigate the effectiveness of stereotactic body radiotherapy (SBRT) boost for the treatment in patients with high-risk prostate cancer (PCa). The main outcome that will be measured will be the quality of life (QoL) of patients. This study is being carried out in Ontario, Canada.  The details PCa is the...

Read More

Searching for patients with prostate cancer to test an experimental treatment before surgery

Posted by on Oct 3, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is investigating the effectiveness of pembrolizumab (Keytruda) plus enzalutamide (Xtandi) in patients with prostate cancer. The primary outcome to be measured will be the absence of cancer on the prostate after it is surgically removed. This study is being conducted in Portland, OR. The details...

Read More

Looking for patients with high-risk prostate cancer to test a combination therapy

Looking for patients with high-risk prostate cancer to test a combination therapy

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aims to examine the effectiveness of niraparib (Zejula) combined with hormone therapy and radiotherapy to treat patients with high-risk prostate cancer. The main outcome to be measured will be how long patients remain cancer-free. This study is recruiting in Philadelphia, PA. The details Prostate cancer occurs mostly...

Read More

Comparison between low and high dose brachytherapy followed by radiation in prostate cancer

Comparison between low and high dose brachytherapy followed by radiation in prostate cancer

Posted by on Jul 3, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to compare urinary symptoms in men with localized prostate cancer treated with either low-dose or high-dose rate brachytherapy in combination with radiation therapy. The authors concluded the both low-dose and high-dose brachytherapy with IMRT was safe and well-tolerated by patients. However, it took longer to recover...

Read More

Should immunotherapy be administered before or after hormone therapy?

Should immunotherapy be administered before or after hormone therapy?

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether immunotherapy with sipuleucel-T (Provenge) shows a greater immune response if administered before or after androgen deprivation therapy (ADT). Authors present preliminary evidence of improved immune cell response when sipuleucel-T was administered first in patients with recurrent prostate cancer at high risk of...

Read More

Men with high-grade disease and low PSA may have more aggressive cancer

Men with high-grade disease and low PSA may have more aggressive cancer

Posted by on Aug 13, 2016 in Prostate cancer | 2 comments

In a nutshell This study examined health outcomes based on PSA (prostate specific antigen) levels in men with high-grade disease. Authors reported more aggressive cancers with low PSA compared to medium PSA. Low PSA appeared to progress similarly to high PSA in men with high-grade disease. Some background Prostate cancer is often graded based on...

Read More

Examining the benefits of combining hormone therapy and radiation therapy

Examining the benefits of combining hormone therapy and radiation therapy

Posted by on Jul 18, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the evidence for combining androgen deprivation therapy (ADT) with radiation therapy for the treatment of high-risk localized prostate cancer. Authors concluded that the combined therapy approach was associated with a survival advantage for intermediate- and high-risk patients.  Some background ADT is a type...

Read More

High-risk prostate cancer: Surgery also a good treatment option for older men

High-risk prostate cancer: Surgery also a good treatment option for older men

Posted by on Jul 11, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined outcomes of different treatment options among older men (aged 70 or older) with high-risk prostate cancer. Authors reported lower disease recurrence rates for prostate surgery compared to radiation and radiation with hormone therapy. Some background Prostate surgery and radiation therapy are both common treatment...

Read More

Adding radiation to hormone therapy is effective for locally advanced prostate cancer

Adding radiation to hormone therapy is effective for locally advanced prostate cancer

Posted by on Jun 6, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefit of combining radiation therapy with androgen deprivation therapy (ADT) in older men and in men with aggressive cancer cells. Researchers reported reduced mortality risks with combination therapy in all groups studied.  Some background Radiation therapy is a common treatment for localized...

Read More